We report the effects of 316 small-molecule APIs, which are either components of approved human cancer therapeutics or of human cancer therapeutics under current or previous clinical investigation, on the catalytic activity of AspH, employing SPE-MS inhibition assays. This evidence concerns the gene ASPH and cancer.